Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data from its Major Depressive Disorder (MDD) portfolio, levomilnacipran and vilazodone, at the American Psychiatric Association (APA) 167th annual meeting (May 3-7, 2014 in New York, N.Y.).
Help employers find you! Check out all the jobs and post your resume.
